Abstract
In this multi-ancestry genome-wide association study (GWAS) and fine mapping study of head and neck squamous cell carcinoma (HNSCC) subsites, we analysed 19,073 cases and 38,857 controls and identified 29 independent novel loci. We provide robust evidence that a 3’ UTR variant in TP53 (rs78378222, T>G) confers a 40% reduction in odds of developing overall HNSCC. We further examine the gene-environment relationship of BRCA2 and ADH1B variants demonstrating their effects act through both smoking and alcohol use. Through analyses focused on the human leukocyte antigen (HLA) region, we highlight that although human papilloma virus (HPV)(+) oropharyngeal cancer (OPC), HPV(-) OPC and oral cavity cancer (OC) all show GWAS signal at 6p21, each subsite has distinct associations at the variant, amino acid, and 4-digit allele level. We also defined the specific amino acid changes underlying the well-known DRB1*13:01-DQA1*01:03-DQB1*06:03 protective haplotype for HPV(+) OPC. We show greater heritability of HPV(+) OPC compared to other subsites, likely to be explained by HLA effects. These findings advance our understanding of the genetic architecture of head and neck squamous cell carcinoma, providing important insights into the role of genetic variation across ancestries, tumor subsites, and gene-environment interactions.
Competing Interest Statement
Tim Waterboer serves on advisory boards for MSD (Merck) Sharp & Dohme. Scott V Bratman is inventor on patents related to cell-free DNA mutation and methylation analysis technologies that are unrelated to this work and have been licensed to Roche and Adela, respectively. Scott V Bratman is a co-founder of and has ownership in Adela.
Funding Statement
This study was funded in part by the European Union's Horizon 2020 research and innovation program under grant agreement No 825771 (HEADSpAcE project) and by the US National Institute of Dental and Craniofacial Research (NIDCR) grants R03DE030257 and R01DE025712. Genotyping using the Oncoarray and the All of Us array was performed at Center for Inherited Disease (CIDR) and funded by NIDCR 1X01HG007780-0 and jointly by NIDCR/NCI X01HG010743. This publication presents data from the Head and Neck 5000 study. The study was a component of independent research funded by the National Institute for Health and Care Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator award to Professor Andy Ness. Round 1 genotyping was funded by US National Institute of Dental and Craniofacial Research (NIDCR) grant 1X01HG007780-0. Round 2 genotyping was funded by World Cancer Research Fund Pilot Grant (grant number: 2018/1792), Above and Beyond Charity (GA2500), Wellcome Trust Research Training Fellowship (201237/Z/16/Z) and Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant number: C18281/A19169). This latter grant also supported Human papillomavirus (HPV) serology. This research has been conducted using the UK Biobank Resource under Application Number 40644. The work of Dr. Polesel is partially supported by Italian Ministry of Health 'Ricerca Corrente'. The University of Pittsburgh head and neck cancer case-control study is supported by US National Institutes of Health grants P50CA097190, P30CA047904 and R01DE025712. Geoffrey Liu is the M. Qasim Choksi Research Chair in Translational Research at University Health Network and University of Toronto and is supported by the Princess Margaret Head and Neck Translational Program, which is supported by philanthropic funds from the Wharton Family, Joe's Team, Gordon Tozer, Reed Fund, and the Riley Family. The University of North Carolina studies were supported in part by grants CA61188 and CA90731 from the National Institutes of Health. Northern Cancer Foundation (Principal Investigator Grants to MSC Conlon, DP Saunders). Rayjean J. Hung is the CIHR Canada Research Chair and the study is supported by the Canadian Cancer Society and Canadian Institute of Health Research. The authors would like to thank all the patients, and their families involved in these studies. Where members are identified as personnel of the International Agency for Research on Cancer/ World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Datasets analyzed in this study are accessible through dbGaP (https://www.ncbi.nlm.nih.gov/gap/) as follows: OncoArray Consortium - Lung Cancer Studies (dbGaP Study Accession: phs001273.v4.p2), OncoArray: Oral and Pharynx Cancer (dbGaP Study Accession: phs001202.v2.p1), National Cancer Institute (NCI) Head and Neck Cancer Study conducted on the HumanOmniExpress-12v1.0 array (dbGaP Study Accession: phs001173.v1.p1), Genome-Wide Association Study of Oral Cavity, Pharynx, and Larynx Cancers in European, North, and South American populations (dbGaP Study Accession: phs002503.v1.p1). Data from the UK Biobank and ALSPAC consortium, are available through their respective access protocols.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
